Limitations : Potential side effects (e.g., agranulocytosis, liver toxicity), variable patient compliance, and risk of relapse upon discontinuation
130 In turn, leads to glomerular damage and the development of glomerulosclerosis
The authors identified BPC-157 as having significant potential and described it as a feasible therapy candidate for conservative treatment of hypovascular and hypocellular soft tissues such as tendon and ligaments, following further development
In the performance world, its frequently obtained from: International pharmacies (legally gray importation) Underground labs (risk of counterfeiting) Peptide research suppliers (legally dubious for human use) Monthly costs for performance-enhancing doses (26 IU/day) typically range from: $800 to $1,500/month for prescription or pharma-grade $300 to $800/month for UGL or gray market HGH Legally, HGH is classified as a Schedule III controlled substance in the United States and is only available via a valid prescription. U.S
Science 283 , 689692 (1999)